Gefticip 250mg Tablet (Gefitinib) – First-Line EGFR Lung Cancer Targeted Therapy
Gefticip 250 (Gefitinib) (generic equivalent to Iressa) is a prescription targeted oncology medication for the treatment of locally advanced or metastatic NSCLC with activating EGFR mutations. As a targeted therapy, it works at a molecular level to slow cancer cell proliferation while sparing healthy tissue.
Composition: Gefitinib (250mg)
Manufacturer: Cipla Ltd
Prescription-only oncology medication. Use only under the direct supervision of a licensed oncologist. Regular blood tests and monitoring are mandatory throughout treatment.
Composition Gefitinib (250mg)
Dosage Form Tablets
Equivalent brand Iressa
Generic Name Gefitinib
Indication Non-small cell lung cancer, Pancreatic cancer
Manufacturer Cipla Ltd
Packaging 30 tablets in 1 bottle
RxMed Kart's sole intention is to ensure that its consumers get expert-reviewed, accurate, and trustworthy information. However, the information contained herein should NOT use as a substitute for a qualified physician's advice. The information provided here is for informational purposes only. This may not cover all possible side effects, drug interactions, or warnings or alerts. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.